Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ PlatformPublished on :
– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]